CN112839672A - 用于减少脂蛋白a形成以及治疗主动脉瓣硬化和主动脉狭窄的组合物和方法 - Google Patents

用于减少脂蛋白a形成以及治疗主动脉瓣硬化和主动脉狭窄的组合物和方法 Download PDF

Info

Publication number
CN112839672A
CN112839672A CN201980057029.4A CN201980057029A CN112839672A CN 112839672 A CN112839672 A CN 112839672A CN 201980057029 A CN201980057029 A CN 201980057029A CN 112839672 A CN112839672 A CN 112839672A
Authority
CN
China
Prior art keywords
antibody
seq
subject
ldl
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980057029.4A
Other languages
English (en)
Chinese (zh)
Inventor
B·C·梁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abby Center Co ltd
Original Assignee
Abby Center Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abby Center Co ltd filed Critical Abby Center Co ltd
Publication of CN112839672A publication Critical patent/CN112839672A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980057029.4A 2018-07-02 2019-07-01 用于减少脂蛋白a形成以及治疗主动脉瓣硬化和主动脉狭窄的组合物和方法 Pending CN112839672A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862693218P 2018-07-02 2018-07-02
US62/693218 2018-07-02
US201862697353P 2018-07-12 2018-07-12
US62/697353 2018-07-12
PCT/US2019/040196 WO2020010024A1 (en) 2018-07-02 2019-07-01 Compositions and methods for reduction of lipoprotein a formation and treatment of aortic valve sclerosis and aortic stenosis

Publications (1)

Publication Number Publication Date
CN112839672A true CN112839672A (zh) 2021-05-25

Family

ID=69060543

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980057029.4A Pending CN112839672A (zh) 2018-07-02 2019-07-01 用于减少脂蛋白a形成以及治疗主动脉瓣硬化和主动脉狭窄的组合物和方法

Country Status (7)

Country Link
US (1) US20210155682A1 (https=)
EP (1) EP3817768A4 (https=)
JP (1) JP7513533B2 (https=)
KR (1) KR20210056325A (https=)
CN (1) CN112839672A (https=)
CA (1) CA3105071A1 (https=)
WO (1) WO2020010024A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
CA3172880A1 (en) * 2020-04-27 2021-11-04 Sotirios Tsimikas Isoform-independent antibodies to lipoprotein(a)
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090169544A1 (en) * 2007-12-28 2009-07-02 Biolnvent International Ab Formulation
US20130243784A1 (en) * 2011-09-16 2013-09-19 Regeneron Pharmaceuticals, Inc. METHODS FOR REDUCING LIPOPROTEIN(a) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
CN106794244A (zh) * 2014-03-17 2017-05-31 赛诺菲生物技术公司 用于降低心血管风险的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727102B1 (en) * 1997-06-20 2004-04-27 Leuven Research & Development Vzw Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins
GB0517878D0 (en) * 2005-09-02 2005-10-12 Bioinvent Int Ab Immunotherapeutic treatment
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
AR076640A1 (es) * 2009-03-06 2011-06-29 Genentech Inc Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090169544A1 (en) * 2007-12-28 2009-07-02 Biolnvent International Ab Formulation
US20130243784A1 (en) * 2011-09-16 2013-09-19 Regeneron Pharmaceuticals, Inc. METHODS FOR REDUCING LIPOPROTEIN(a) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
CN106794244A (zh) * 2014-03-17 2017-05-31 赛诺菲生物技术公司 用于降低心血管风险的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KELLEY R. BRANCH等: "Aortic Valve Sclerosis As a Marker of Active Atherosclerosis", CURRENT CARDIOLOGY REPORTS, vol. 4, pages 3 - 4 *
杨瑞民等: "介入医学", 31 July 2007, 河南科学技术出版社, pages: 179 - 181 *
王晓虹;王苏平;王翠;门洋;王虹;赵树芳;: "颅内外动脉粥样硬化狭窄分布与脂蛋白胆固醇及载脂蛋白的关系", 脑与神经疾病杂志, vol. 24, no. 06, pages 349 - 354 *

Also Published As

Publication number Publication date
JP7513533B2 (ja) 2024-07-09
JP2021529766A (ja) 2021-11-04
EP3817768A1 (en) 2021-05-12
US20210155682A1 (en) 2021-05-27
EP3817768A4 (en) 2022-07-06
KR20210056325A (ko) 2021-05-18
CA3105071A1 (en) 2020-01-09
WO2020010024A1 (en) 2020-01-09

Similar Documents

Publication Publication Date Title
JP7785107B2 (ja) 抗プロ／潜在型ミオスタチン抗体およびその使用
US20240374718A1 (en) Anti-pro/latent-myostatin antibodies and uses thereof
US12458694B2 (en) Methods for treatment of accelerated atherosclerosis and rheumatoid arthritis with an anti-Apo B100 antibody
BRPI0822049A2 (pt) tratamento de cistite intersticial
JP2023089245A (ja) Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用
JP6277125B2 (ja) ホスホリルコリンに対する新規抗体
CN112839672A (zh) 用于减少脂蛋白a形成以及治疗主动脉瓣硬化和主动脉狭窄的组合物和方法
US20250326831A1 (en) Methods for treating disease using psmp antagonists
HK40112898A (zh) 抗alk1抗体及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination